Mr. French currently serves as Chairman of the Company’s Board of Directors. Mr. French is a founder and Managing Director of Santé Ventures, an investor in early stage life science and healthcare companies. Mr. French is the past President and Chief Executive Officer of the Ascension Health system and creator of the Ascension Health Ventures corporate fund. Immediately prior to founding Santé Ventures, Mr. French served as a healthcare Venture Partner with Austin Ventures. With more than 25 years of experience in the field of healthcare and a vast network of relationships, he is one of the most respected and recognized leaders in the industry. He is known as an innovative and creative leader, a successful risk taker, and superb developer of people and organizations. Mr. French serves on the board of Herman Miller (MLHR) and is a prior board member of Ascension Health, Catholic Healthcare West and the Catholic Healthcare Association. Mr. French holds a B.S. Degree from Trevecca Nazarene College in Nashville, Tennessee and a Masters in Hospital and Health Services Administration from Xavier University in Cincinnati, Ohio.
Alex joined Endeavour Vision in 2015, where he serves as senior investment director, investing in medical technology and digital health investments across multiple therapeutic areas.Alex brings more than two decades of business and strategy experience in both medical device and high-technology companies. He currently represents Endeavour Vision on the boards of EndoStim, Relievant, VentureMed, and VertiFlex, and serves as a board observer at Gynesonics. He is a member of the steering committee for PCR Innovators’ Day and serves as both a jury member and expert panelist for the Healthtech Summit.
Prior to joining the Endeavour Vision team, Alex spent nine years with Biosensors International Group, an interventional cardiology company, where he served as vice president of business development. He previously worked with LogiSpring Ventures, MicroStrategy and McKinsey & Co. Alex holds an MBA from INSEAD and a BSFS, magna cum laude, from Georgetown University.
Brian Farley has over 35 years of experience in the medical device and healthcare industry. In addition to his role as a board member at EndoStim, Mr. Farley currently sits on the board of three medical device companies serving as Chairman of both Myoscience Inc. and Neuronetics Inc. (NASDAQ: STIM) and serves as a director of Neurolutions Inc.
Recently, Mr. Farley served as Chairman of the Board of Entellus Medical, Inc. and also served as the company’s Chief Executive Officer from 2010 to 2015, leading the company in a successful IPO in early 2015. In February 2018, Stryker Corporation completed an acquisition of Entellus Medical. Prior to joining Entellus, Mr. Farley was President and CEO of VNUS Medical Technologies, Inc. He joined VNUS in 1995 as the first employee and led the company to become the market leader in the minimally invasive treatment of venous insufficiency. Mr. Farley led VNUS in a successful IPO in 2004 and in June 2009, VNUS was sold to Covidien. Prior to VNUS, Mr. Farley held various management and executive positions in research and development, clinical research and business development for Guidant Corporation, and in the medical division of Eli Lilly and Company. Mr. Farley holds both a B.S. in Engineering and an M.S. in Electrical Engineering with a Biomedical Engineering major from Purdue University.